Last reviewed · How we verify
NCT06849349
EXAMINATION OF SOME MOLECULES IN PLACENTAS OF PATIENTS WITH PLACENTA PREVIA, PLACENTA PERCREATA
trial in Placenta Percreta, Third Trimester in 48 participants. Currently enrolling.
20 June 2025
Quick facts
| Lead sponsor | Celal Bayar University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 20 February 2025 |
| Primary completion | 20 June 2025 |
| Estimated completion | 20 November 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Placenta Percreta, Third Trimester — all drugs for Placenta Percreta, Third Trimester →
- Placenta Previa — all drugs for Placenta Previa →
Sponsor
Celal Bayar University
Who can join
Adults 18 to 50, female only, with Placenta Percreta, Third Trimester or Placenta Previa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the presence of bleeding. Studies show that the increased frequency of placenta previa is associated with increased cesarean section rates and maternal age (1). Furthermore, the effects of placenta previa on maternal and fetal morbidity can be reduced with proper management (2). Placenta percreata is a condition in which the placenta invades the myometrium (uterine muscle) and serosa (outer surface of the uterus). This can make postpartum detachment of the placenta difficult, leading to severe bleeding and complications. Placenta perforata is often associated with placenta previa and may require surgical intervention. Ultrasonography and magnetic resonance imaging (MRI) are used to diagnose this condition. Risk factors include previous cesarean deliveries and placenta previa (3). Placenta percreata requires careful management as it increases the risk of maternal mortality and morbidity (4). In this study, we aimed to investigate the levels of decorin, laminin, collagen-1, TGFβ-1, PDGF in placentas of pregnant women with placenta percreata and previa.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06849349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Celal Bayar University trials
Trials by the same sponsor.
- NCT07414238 — Effect of Vibration and Non-Vibration Foam Rolling · NA · completed
- NCT07344272 — The Effects of Proprioceptive Neuromuscular Facilitation · NA · recruiting
- NCT06994013 — Acute Effects of High- vs. Low-frequency Vibration Foam Rolling · NA · completed
- NCT06976632 — Effect of Helfer Skin Tap and Cold Application on Pain and Hemodynamics During Vaccination · NA · recruiting
- NCT06909461 — The Effect of Pain Neuroscience Education · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06849349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Celal Bayar University
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06849349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing